This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Guidelines and recommendations for ADHD in children and adolescents. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011
Evidence-based recommendations support the use of stimulants as first-line therapy and the consideration of symptom profile in the use of long- or short-acting formulations when treating children and adolescents with severe ADHD.
The drug payment information presented in this summary report reveals substantial use of health care budgets to reimburse long-acting formulations. In 2010, expenditures on long-acting medications had exceeded $35 million (or 77% of total expenditures on ADHD medications) by public drug plans in Canada.
Subject indexing assigned by CRD
Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Practice Guidelines as Topics
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: firstname.lastname@example.org
Date abstract record published